ANIP · Ani Pharmaceuticals Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 7, 2026TL;DR. ANI posted record Q2 2026 results with 26% revenue growth and a 32% adjusted EBITDA increase, but lowered its full-year Cortrophin Gel revenue guidance to $520–$540M (from $540–$575M) to reflect first-half results.
- + Record Q2 revenue of $266M, up 25.9% year-over-year
- + Cortrophin Gel net revenue grew 43.5% to $117.1M, a record, with strong Q3 momentum
- + Adjusted non-GAAP EBITDA rose 32.4% to a record $71.6M
- + Rare disease sales force expanded by 50% to ~180 reps for gout, with very positive early demand indicators
- + Generics revenue grew 9.7% to $99.1M with 12 launches YTD, on track for 15+ in 2026
- − Full-year Cortrophin Gel revenue guidance lowered to $520–$540M from $540–$575M
- − Non-GAAP gross margin compressed ~230 bps to 62.6% on product mix
- − Brands revenue declined 10.5% to $11.8M from demand normalization
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Adjusted Diluted Weighted-Average Shares Outstanding (excluded shares) non-GAAP | 345,000 | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANIP
this stock
Ani Pharmaceuticals Inc
|
$1.67B | -8.0% | +2.5% | 15.6 | 10.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -4.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.9% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -11.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANIP | -2.4% | +1.0% | -9.4% | -0.8% | -8.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -1.7% | +0.9% | -21.5% | -0.2% | -19.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.